MARKET

IKT

IKT

Inhibikase Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.000
-0.050
-2.44%
After Hours: 2.070 +0.07 +3.50% 17:11 09/21 EDT
OPEN
2.060
PREV CLOSE
2.050
HIGH
2.160
LOW
2.000
VOLUME
135.07K
TURNOVER
--
52 WEEK HIGH
11.80
52 WEEK LOW
1.740
MARKET CAP
50.27M
P/E (TTM)
-2.8361
1D
5D
1M
3M
1Y
5Y
Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced tha...
PR Newswire - PRF · 09/07 12:00
Inhibikase Therapeutics Q2 EPS $(0.22) Down From $(0.05) YoY, Sales $1.36M Up From $219.59K YoY
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.22) per share. This is a 340 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $1.36 million in
Benzinga · 08/16 20:48
-- Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Reports Q2 Revenue $1.4M
MT Newswires · 08/16 17:11
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
Stocks That Hit 52-Week Lows On Thursday
    During Thursday's morning trading, 83 companies set new 52-week lows.
Benzinga · 08/12 14:06
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 08/10 18:42
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 07/27 11:48
BRIEF-Inhibikase Therapeutics Inc - Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation Of Ikt-148009 In Parkinson's Patients
reuters.com · 07/26 14:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IKT. Analyze the recent business situations of Inhibikase Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IKT stock price target is 13.50 with a high estimate of 15.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 14
Institutional Holdings: 3.79M
% Owned: 15.10%
Shares Outstanding: 25.13M
TypeInstitutionsShares
Increased
4
424.69K
New
9
3.24M
Decreased
0
0
Sold Out
4
31.62K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
  • All
  • Financials
  • Insiders
More
About IKT
Inhibikase Therapeutics Inc. is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The Company’s lead product candidate, IkT-148009 is for the treatment of PD, and for the treatment of gastrointestinal (GI), complications that arise as early symptoms of PD in patients. The Company’s kT-148009, is a brain penetrant c-Abl protein kinase inhibitor that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the GI tract. The Company’s products candidate also include IKT-001Pro, which is a prodrug of the anticancer agent Imatinib, and used as a treatment for stable-phase chronic myelogenous leukemia (CML), and IKT-01427 for progressive multifocal leukoencephalopathy (PML).

Webull offers kinds of Inhibikase Therapeutics Inc stock information, including NASDAQ:IKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IKT stock methods without spending real money on the virtual paper trading platform.